What is Eupraxia?
Eupraxia Pharmaceuticals Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of innovative technologies within the life sciences sector. The company's primary focus lies in its lead product candidates: EP-104IAR, currently in Phase III trials for knee osteoarthritis pain relief; EP-104GI, undergoing Phase II trials for eosinophilic esophagitis; and EP-104, in preclinical stages for various inflammatory joint conditions and esophageal disorders. Eupraxia also has a strategic interest in developing product candidates for oncology. Originally incorporated as Plaza Capital Partners Inc. in 2011, the company rebranded to Eupraxia Pharmaceuticals Inc. in May 2012, signaling its commitment to pharmaceutical innovation.
How much funding has Eupraxia raised?
Eupraxia has raised a total of $70M across 2 funding rounds:
Debt
$8M
Share Placement
$62M
Debt (2021): $8M with participation from Silicon Valley Bank
Share Placement (2024): $62M, investors not publicly disclosed
Key Investors in Eupraxia
Silicon Valley Bank
Silicon Valley Bank is a commercial bank that provides financial services to technology and venture capital-backed companies. Its involvement suggests a focus on supporting growth-stage technology and life science ventures.
What's next for Eupraxia?
With the recent major strategic investment and a total funding base of $70M, Eupraxia Pharmaceuticals is poised for significant advancements in its clinical development programs. The enterprise-level capital injection is expected to accelerate the progression of its key candidates, EP-104IAR and EP-104GI, through their respective late-stage trials. This strategic financing will likely bolster research and development efforts, potentially expanding the company's therapeutic focus into oncology and other inflammatory conditions. The company's trajectory suggests a move towards commercialization readiness, contingent on successful trial outcomes and further strategic partnerships.
See full Eupraxia company page
